QUIDELORTHO CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.4 USD | +3.38% |
|
+0.25% | -45.18% |
| Apr. 02 | QuidelOrtho Shares Fall on Decision to Withdraw FDA 510(k) Submission for Savanna RVP4+ Assay | MT |
| Apr. 02 | QuidelOrtho Gets US FDA Clearance For QuickVue COVID-19 Test | MT |
Financials (USD)
| Sales 2024 * | 2.8B | Sales 2025 * | 2.91B | Capitalization | 2.7B |
|---|---|---|---|---|---|
| Net income 2024 * | -72M | Net income 2025 * | 80M | EV / Sales 2024 * | 1.68 x |
| Net Debt 2024 * | 2B | Net Debt 2025 * | 1.67B | EV / Sales 2025 * | 1.5 x |
| P/E ratio 2024 * |
-37.5
x | P/E ratio 2025 * |
34
x | Employees | 7,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.96% |
More Fundamentals
* Assessed data
More news
Latest transcript on QuidelOrtho Corporation
More recommendations
More press releases
| 1 day | +3.38% | ||
| 1 week | +0.25% | ||
| Current month | -15.73% | ||
| 1 month | -13.68% | ||
| 3 months | -44.01% | ||
| 6 months | -39.64% | ||
| Current year | -45.18% |
1 week
37.78
40.82
1 month
37.7849.08
Current year
37.7875.82
1 year
37.7895.02
3 years
37.78180.06
5 years
37.78306.72
10 years
13.21306.72
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Iskra
CEO | Chief Executive Officer | 54 | 22-04-30 |
Robert Bujarski
PSD | President | 55 | 05-06-30 |
Joseph Busky
DFI | Director of Finance/CFO | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kenneth Widder
BRD | Director/Board Member | 71 | 13-12-31 |
Kenneth Buechler
CHM | Chairman | 70 | - |
Mary Polan
BRD | Director/Board Member | 80 | 92-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.24% | 215 M€ | +11.92% | - | |
| 1.92% | 2 M€ | +5.19% | ||
| 1.62% | 8 M€ | -.--% | ||
| 0.98% | 16 M€ | -7.93% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 40.4 | +3.38% | 1,192,796 |
| 24-04-22 | 39.08 | -0.10% | 907,832 |
| 24-04-19 | 39.12 | +2.25% | 1,106,265 |
| 24-04-18 | 38.26 | -1.16% | 1,039,115 |
| 24-04-17 | 38.71 | -3.95% | 754,606 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
40.4
USD
Average target price
54.73
USD
Spread / Average Target
+35.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.18% | 2.7B | |
| +15.62% | 1.83B | |
| -2.14% | 1.63B | |
| +21.84% | 1.2B | |
| -13.27% | 995M | |
| -21.67% | 896M | |
| -6.04% | 726M | |
| -15.76% | 701M | |
| +12.74% | 527M | |
| -.--% | 302M |
- Stock Market
- Equities
- QDEL Stock
